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ABSTRACT 
Background: The frequency of migraine headache changes at various times of a 
woman’s reproductive cycle.  Menarche, menses, pregnancy, and perimenopause may 
carry a different migraine risk conceivably because of fluctuating estrogen levels, and in 
general migraine frequency is associated with falling estrogen levels.  Given the strong 
relationship between endogenous estrogen levels and breast cancer risk, migraine 
sufferers may experience a reduced risk of breast cancer.  
Methods: We combined data from two population-based case-control studies to 
examine the relationship between migraine and risk of postmenopausal invasive breast 
cancer among 1,199 ductal carcinoma cases, 739 lobular carcinoma cases, and 1,474 
controls 55-79 years of age.  Polytomous logistic regression was used to estimate odds 
ratios and 95% confidence intervals; all statistical tests were 2-sided. 
Results: Women who reported a clinical diagnosis of migraine had reduced risks of 
ductal carcinoma (IDC) [odds ratio (OR): 0.67, 95% confidence interval (CI): 0.54-0.82] 
and lobular carcinoma (ILC) (OR: 0.68, 95% CI: 0.52-0.90).  These associations were 
primarily limited to hormone receptor positive tumors as migraine was associated with a 
0.65-fold (95% CI: 0.51-0.83) reduced risk of estrogen receptor (ER) 
positive/progesterone receptor (PR) positive ductal carcinoma.  The reductions in risk 
observed were seen among migraine sufferers who did and did not use prescription 
medications for their migraines. 
Conclusions: These data suggest a history of migraine is associated with a decreased 
risk of breast cancer, particularly among ER+/PR+ ductal and lobular carcinomas.  
Because this is the first study to address an association between migraine history and 
breast cancer risk, additional studies are needed to confirm this finding.   
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INTRODUCTION 
Migraine is a common neurological disorder characterized by episodic attacks of 
moderate to severe throbbing headache which may be disabling and accompanied by 
nausea, vomiting, photophobia and/or phonophobia.  An estimated 15-18% of the U.S. 
female population has either diagnosed or undiagnosed migraine, with the highest 
prevalence occurring in women aged 25 to 55 years (1, 2).  Several observations 
support a relationship between female sex hormones and migraines.  The prevalence of 
migraine in women is roughly two to three times higher than that in men.  Low levels of 
serotonin are clearly associated with increased frequency of migraine, and estrogen 
positively regulates serotonin (3-5).  In addition, the frequency of migraine in women 
varies during menarche, menses, pregnancy, and menopause, a pattern which may be 
attributable to fluctuating estrogen levels (3).  Of particular relevance, migraines in 
women are often associated with estrogen withdrawal states and low serotonin levels.  
Migraine frequency increases immediately before or during menses when endogenous 
estrogen levels decline in cycling premenopausal women, and it also increases during 
the hormone free week of oral contraceptive use (6-8).  In contrast, pregnancy, a high 
estrogen state, is associated with migraine remission for the majority of migraine 
sufferers (9), particularly in the second and third trimesters.  Though not typically used 
as a first-line of treatment for menstrual-associated migraine, hormonal treatments, 
particularly those administered during the hormone-free week of OC users, may have a 
beneficial effect on female migraineurs unless there is a contraindication for estrogen 
supplementation (7).  Given that lifetime estrogen exposure is correlated with breast 
cancer risk (10), the occurrence of migraines in women, which also has a relationship to 
estrogen, may be related to breast cancer risk.  However, to date, no study has 
evaluated this potential association. 
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The purpose of this study is to assess the hypothesis that migraine is associated 
with a reduced risk of breast cancer using data from two population-based case-control 
studies that included postmenopausal women 55-79 years of age. 
METHODS 
Subjects 
Women from two population-based case-control studies conducted in the 
Seattle-Puget Sound region in Washington state were used for this analysis.  The 
earlier of these two studies included women aged 65-79 years diagnosed with invasive 
breast cancer between 1997-1999 regardless of histological type.  Details of the 
methods used in this study have been published previously (11).  The Cancer 
Surveillance System (CSS), a population-based cancer registry that monitors cancer 
incidence in western Washington, was used to ascertain cases.  Of 1,210 eligible cases 
identified 975 (81%) were interviewed.  Records from the Centers for Medicare and 
Medicaid Service were used to identify female controls without breast cancer from the 
general population of King, Pierce, and Snohomish counties who were frequency 
matched 1:1 to cases on 5-year age groups, year, and county of residence.  Of the 
1,365 eligible controls identified, 1,007 (74%) were enrolled and interviewed. 
The more recently completed of these two studies enrolled women aged 55-74 
years diagnosed with invasive breast cancer between 2000-2004.  Because the 
purpose of this study was to evaluate the etiology of lobular carcinomas, sampling of 
cancer cases differed by histological type.  Details of the methods used in this study 
were recently published (12).  The CSS was used to identify cases.  Of the 1,251 
eligible cases identified 1,044 (83%) were subsequently enrolled in the study and 
interviewed including 501 ductal and 543 lobular cases.  Random digit dialing was used 
to identify women without breast cancer from the general population who were the same 
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age and reference year as cases.  A total of 9,876 telephone numbers were identified 
and 87% were successfully screened for eligibility.  Of the 660 eligible controls 
identified, 469 (71%) were enrolled and interviewed.  
Both studies used similar protocols that were approved by the Fred Hutchinson 
Cancer Research Center Institutional Review Board, and written informed consent was 
obtained from all participants.  Both studies excluded all women with a prior history of in 
situ or invasive breast cancer.  All cases and controls were interviewed in-person by a 
trained interviewer.  Data were collected via standardized questionnaires that were very 
similar across the two studies.  Women were asked about exposures occurring before 
their reference date, which for cases was defined as the date of their breast cancer 
diagnosis.  Control reference dates were assigned based on the expected distribution of 
case reference dates.  With respect to migraine history, women were asked about 
whether they were ever clinically diagnosed with migraine (yes/no), age at migraine 
diagnosis, ever use of prescription medications for migraine, and age of first prescription 
migraine medication use.  Information on specific medications used to treat migraine, 
including name, dose, and duration was not collected.  The two IDC cases, one ILC 
case, and two controls with an unknown history of migraine were excluded from this 
analysis.  In addition, detailed information on other known or suspected breast cancer 
risk factors, including reproductive history, anthropometric characteristics, use of 
exogenous hormones, family history of breast cancer, and lifestyle characteristics, was 
collected. 
Cases were classified as IDC or ILC (including both pure lobular and mixed 
ductal-lobular carcinomas) based on a centralized review of pathology reports 
conducted at the Fred Hutchinson Cancer Research Center.  Since the more recently 
completed study only enrolled ductal and lobular cases, the 500 ductal and 542 lobular 
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cases were included in this analysis.  Since the earlier study enrolled cases regardless 
of histology this analysis included the 699 ductal and 197 lobular cases enrolled, but 
excluded the 78 cases with other histological types of breast cancer.  In total, 1,199 IDC 
and 739 ILC cases with a known migraine history were included in this analysis.  Data 
on ER/PR status was also centrally ascertained through this review.  The 116 (6%) 
cases with an unknown ER/PR status were excluded from the ER/PR analyses. 
Statistical Analysis 
In order to compare IDC and ILC cases to controls, polytomous logistic 
regression was used to calculate odds ratios (ORs) and 95% confidence intervals (13).  
All analyses were adjusted for age (continuous) and reference year.  The referent 
category was women with no history of migraine.   Variables considered as potential 
confounders or effect modifiers included race, income, marital status, education, age at 
menarche, parity, age at first birth, type of menopause, age at menopause, duration of 
oral contraceptive use, use of hormone therapy, family history of breast cancer, body 
mass index (BMI), smoking status, and average alcohol intake.  None of these variables 
changed our risk estimates by more than 10%, and so none were included as 
confounders in the final statistical models.  Effect modification was assessed using 
likelihood ratio testing, and none of these variables were observed to be statistically 
significant effect modifiers (p-value for interaction<0.05).  We also assessed 
heterogeneity across the ORs for migraine history across the two histological types of 
breast cancer studied by testing the null hypothesis that each of these ORs was 
equivalent to each other (test of homogeneity of ORs).  Statistical tests were two-sided 
and p-values <0.05 were considered statistically significant.  All analyses were 
conducted using Stata 9.2 (Stata Corp, College Station, TX). 
RESULTS 
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Compared to controls, both IDC and ILC cases were more likely than controls to 
be current users of combined estrogen and progestin hormone therapy and have a first-
degree family history of breast cancer (Table 1).  ILC cases were somewhat more likely 
than both IDC cases and controls to be younger, more educated, and nulliparous.  
Women who reported a clinical diagnosis of migraine had a 33% reduced risk of 
IDC (95% confidence interval (CI): 0.54-0.82) and a 32% reduced risk of ILC (95% CI: 
0.52-0.90) compared to women with no history of migraine (Table 2). These reductions 
in risk did not vary substantially by age at migraine diagnosis or by history of ever using 
prescription migraine medications.  The test for homogeneity of risk across histology 
associated with a history of migraine suggests no difference in ORs (p=0.68).  
Specifically, compared to women with no history of migraine, migraineurs had 
reduced risks of ER+/PR+ IDC (OR: 0.65, 95% CI: 0.51-0.83), ER+/PR- IDC (OR: 0.49, 
95% CI: 0.27-0.88) and ER+/PR+ ILC (OR: 0.63, 95% CI: 0.47-0.85), but not of ER-/PR- 
IDC (OR: 0.87, 95% CI: 0.56-1.36) or ER+/PR- ILC (OR: 0.80, 95% CI: 0.47-1.36) 
(Table 3).  In addition, given that the ages of the women and the type of controls 
differed by study, we analyzed risk of breast cancer associated with migraine history 
across both contributing studies separately.  In the earlier of the two studies, which 
enrolled women 65-79 years of age, a history of migraine was associated with a 0.71-
fold (95% CI: 0.53-0.94) reduced risk of IDC, but not a reduced risk of ILC (OR: 1.00, 
95% CI: 0.66-1.51).  In the more recently completed study, which enrolled women 55-74 
years of age, a history of migraine was associated with a 0.60-fold (95% CI: 0.43-0.83) 
reduced risk of IDC and a 0.54-fold (95% CI: 0.39-0.75) reduced risk of ILC.  Risk did 
not differ significantly by age at migraine diagnosis for either study. 
DISCUSSION 
 9
This study has several limitations.  Information on migraine history was based on 
self-report and thus is subject to bias.  However, given the severity of migraine and its 
associated morbidity, it is likely that recall of migraine history will be accurate.  In 
addition, we only captured information on migraine that was diagnosed by a physician 
or other health professional.  It has been reported that approximately 27-59% of 
migraine sufferers are never clinically diagnosed (14-16).  However, any 
misclassification resulting from this would most likely be non-differential, particularly 
since there are no reports in the literature on the association between migraine and 
breast cancer risk.  Our lack of data on migraine characteristics, particularly their 
relationship to the menstrual period and other reproductive events, and migraine 
treatments is of concern since this may be relevant to breast cancer risk.  Specifically, 
we did not collect data on the use of non-steroidal anti-inflammatory drugs (NSAIDs), 
which are associated with a modest reduction in breast cancer risk (17), although not all 
studies have observed a reduction in risk (18).     
Our results suggest that a history of diagnosed migraine may be associated with 
a reduced risk of breast cancer in postmenopausal women, and particularly with a 
reduced risk of ER+/PR+ tumors.  These reductions were observed in women with 
either IDC or ILC tumors and did not vary by history of prescription migraine medication 
use or age at migraine diagnosis.  To our knowledge, this is the first study to address 
the association between a history of diagnosed migraine in women and breast cancer 
risk. 
Based on previous studies documenting the influence of hormonal changes on 
migraine, it is plausible that migraine is associated with a reduced risk of IDC and ILC 
through hormonal pathways.  Several studies have observed an association between 
hormonally associated events (i.e. menarche, menses, pregnancy, and menopause) 
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and migraine frequency and severity (3, 8, 9, 14, 19-25).  Approximately 60% of female 
migraineurs report an association of migraine with menses, suggesting that hormonal 
fluctuations, particularly the withdrawal of estrogen, triggers migraine (8).  Indeed, 7% to 
14% of women with migraine report that their migraines exclusively occur two days 
before to three days after the onset of the menstrual period (20).   
There are several other lines of evidence that also support the association 
between falling estrogen levels and migraine occurrence.  Women taking oral 
contraceptives have more migraine headaches during their hormone-free week, 
particularly during the first few days of this week (26).  Two studies have also shown 
that women with menstrual migraine treated with estradiol experience reductions in 
migraine frequency, duration, and severity compared to women given placebo (27, 28).  
Migraine frequency also decreases during pregnancy when estrogen levels substantially 
increase (8).  In one study, 79% of women reported total migraine remission by their 
third trimester (29).  Menopause is associated with low levels of endogenous steroid 
hormones.  In one study, two-thirds of women with premenopausal migraine reported 
fewer migraines after menopause (24). Together these observations further indicate that 
stable endogenous estrogen levels, and perhaps the use of exogenous estrogens, are 
inversely associated with migraine frequency.  While it may be important for future 
studies to measure serum hormone levels in migraineurs, given that frequent short-term 
fluctuating endogenous estrogen levels may be most likely to trigger migraine attacks, it 
is probably impractical to effectively measure endogenous hormone levels in a large 
group of migraineurs over a long period of time.  
Hormones may be relevant to the pathophysiology of migraine because of their 
impact on serotonin (5-HT), a central and peripheral neurotransmitter.  While the 
mechanisms through which serotonin participates in the migraine syndrome is 
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incompletely understood, current evidence suggests that the triptans, specific serotonin 
derivatives, prevent the release of nociceptive and inflammatory peptides and cause 
vasoconstriction of meningeal vasculature.  It also has been shown that triptans bind 
centrally in the brainstem as well, possibly modulating central transmission (30).  
Hormones and serotonin have been linked in primate studies indicating that both 
estrogen and progesterone increase serotonin production and transport (4, 31).  Given 
these observations and the well established positive association between endogenous 
circulating hormone levels and risk of hormone receptor positive breast cancer (32-34), 
we hypothesized that migraine may be particularly associated with a reduced risk of 
hormone receptor positive tumors.  Indeed, we found that a history of migraine was 
strongly associated with reduced risks of hormone receptor positive tumors, but not with 
ER-/PR- tumors.  
 However, it is also possible that medications used to treat or prevent migraine, 
rather than the occurrence of migraines itself, may be responsible for the reductions in 
risk we observed.  In particular, several studies of non-steroidal anti-inflammatory drugs 
(NSAIDs) have shown that NSAID use is associated with a reduced risk of breast 
cancer, especially hormone receptor positive tumors (17, 35, 36).  NSAIDs are a 
common treatment for migraine and are typically taken at the time of onset of migraine 
symptoms. NSAIDs likely reduce breast cancer risk through inhibition of 
cyclooxygenase (COX)-2, the rate-limiting enzyme in the prostaglandin pathway (37).  
While we could not assess the impact of use of over the counter migraine medications 
on our risk estimates because these data were not collected, we did find that both users 
and non-users of prescription migraine medications had reduced risks of breast cancer.  
In general, however, prescription migraine medications, including beta-blockers, 
calcium-channel blockers, and tricyclic antidepressants, have not been associated with 
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a reduced risk of breast cancer (38-42).  There are no reports in the literature regarding 
any association between breast cancer risk and the use of other classes of migraine 
medications including anti-convulsants, triptans, and ergot derivatives.   
In summary, this is the first study to suggest that migraine may be associated 
with a reduced risk of breast cancer.  Migraine is primarily a premenopausal disease 
and the studies focusing on hormone levels in premenopausal women in relation to 
breast cancer are few and the evidence is mixed (43-45), thus this could expand our 
understanding of the impact hormonal exposures during a woman's premenopausal 
years can have on her risk of developing breast cancer when she is postmenopausal.  
Previous studies investigating the relationship between hormonally-related factors and 
migraine indicate this association is biologically plausible, and the reductions in risk we 
observed were confined to hormone receptor positive tumors, lending further support to 
a possible underlying hormonal mechanism. While we cannot rule out that NSAID use 
may be partly or entirely responsible for this reduction in breast cancer risk, two 
observations suggest that a history of migraine, rather than medications used for 
migraine, is independently related to risk.  First, the association between NSAID use 
and breast cancer risk is modest, with a meta-analysis of six cohort studies and eight 
case-control studies finding that regular use of NSAIDs is associated with only an 18% 
(95% CI: 11%-25%) reduced risk of breast cancer (17).  Here we observed that women 
with migraine had a 33% reduced risk of breast cancer, which is higher than the 18% 
reduction associated with NSAID use.  Second, NSAID use for migraine is episodic.  
Several studies of NSAID use in relation to breast cancer risk indicate that regular use, 
not episodic use, is what is most strongly protective of breast cancer.  Indeed, both 
prospective cohort and retrospective case-control studies have observed a decreased 
risk of breast cancer among regular NSAID users but not among non-regular NSAID 
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users (36, 46-49), though it should be noted that prospective data from several other 
large cohort studies have found no association between regular use of NSAIDs and 
breast cancer risk (50-53).  It is uncertain if the majority of migraine sufferers would in 
fact be regular NSAID users.  While the public health importance of these findings is 
currently unclear, we feel additional studies are certainly needed to clarify this issue.  
We are not suggesting that expensive large-scale studies are needed to confirm these 
data, but further work that can account for NSAID use is required to confirm and expand 
upon our findings given that this is the first report of this association in the literature.  
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Table 1. Selected characteristics of controls, invasive ductal carcinoma cases, and invasive 
lobular carcinoma cases 
 
 Controls Ductal carcinoma Lobular carcinoma 
 n=1,474 (%) n=1,199 (%) n=739 (%) 
Reference age, yrs    
   55-59 137 (9.3) 140 (11.7) 162 (21.9) 
   60-64 121 (8.2) 125 (10.4) 139 (18.8) 
   65-69 442 (30.0) 341 (28.4) 189 (25.5) 
   70-74 478 (32.4) 380 (31.7) 195 (26.4) 
   75-79 296 (20.1) 213 (17.7) 54 (7.3) 
Race  
   White (non-Hispanic) 1346 (91.3) 1116 (93.1) 688 (93.1) 
   Black 45 (3.1) 22 (1.8) 16 (2.2) 
   Asian/Pacific Islander 38 (2.6) 35 (2.9) 11 (1.5) 
   Other/unknown 45 (3.0) 26 (2.2) 24 (3.2) 
Education  
   Less than high school 177 (12.0) 127 (10.6) 53 (7.2) 
   High school 520 (35.3) 403 (33.6) 221 (29.9) 
   Some college 467 (31.7) 407 (33.9) 238 (32.2) 
   College/college grad 309 (21.0) 262 (21.9) 227 (30.7) 
   Missing 1 0 0 
Parity  
Nulliparous 130 (8.8) 126 (10.5) 99 (13.4) 
Parous 1344 (91.2) 1073 (89.5) 640 (86.6) 
Age at first birth, yrs  
14-19 273 (20.4) 201 (18.8) 124 (19.5) 
20-24 650 (48.5) 519 (48.6) 306 (48.0) 
25-29 305 (22.7) 244 (22.8) 136 (21.4) 
30-42 113 (8.4) 105 (9.8) 71 (11.1) 
Missing 133 130 102 
Use of oral contraceptives, months  
   0 907 (63.4) 721 (63.0) 339 (49.2) 
   6-59 297 (20.8) 219 (19.1) 193 (28.0) 
   60-409 227 (15.9) 204 (17.8) 157 (22.8) 
   Missing 43 55 50 
Recency of menopausal hormone therapy (HT) use 
   Never user 433 (32.4) 323 (29.9) 134 (19.3) 
   Former user of HT 246 (18.4) 185 (17.1) 96 (13.9) 
   Current EHT user 450 (33.6) 297 (27.5) 195 (28.1) 
   Current CHT user 209 (15.6) 276 (25.5) 268 (38.7) 
   Missing 136 118 46 
First-degree family history of breast cancer  
   No 1153 (83.4) 878 (77.3) 556 (77.3) 
   Yes 229 (16.6) 258 (22.7) 163 (22.7) 
   Missing 92 63 20 
Body mass index, quartiles (kg/m2)  
   ≤23.16 363 (25.4) 265 (22.6) 210 (29.0) 
   23.17-26.44 372 (26.1) 309 (26.4) 154 (21.3) 
   26.45-30.82 343 (24.0) 283 (24.1) 200 (27.6) 
   ≥30.83 350 (24.5) 315 (26.9) 160 (22.1) 
   Missing 46 27 15 
Abbreviations: EHT=estrogen hormone therapy, CHT=combined hormone therapy. 
 Table 2. Relationship between a history of migraine and risks of invasive ductal and invasive lobular breast carcinomas 
 
 
Controls 
 (n=1,474) 
Ductal carcinoma 
(n=1,199) 
Lobular carcinoma 
(n=739) 
 n (%) n (%)  OR* (95% CI) n (%)  OR* (95% CI) 
Never diagnosed with migraine 1,202 (82) 1,037 (87)  1.00 (ref) 630 (85)  1.00 (ref) 
 
Ever diagnosed with migraine 272 (19) 162 (14)  0.67 (0.54-0.82)† 109 (15)  0.68 (0.52-0.90)† 
 
 Age at migraine diagnosis, yrs  
 <20 73 (5) 32 (3)  0.50 (0.33-0.76)† 23 (3)  0.55 (0.33-0.91)† 
 20-39 110 (8) 80 (7)  0.83 (0.62-1.13) 48 (7)  0.77 (0.53-1.12) 
 ≥40 89 (6) 50 (4)  0.62 (0.43-0.89)† 36 (5)  0.62 (0.41-0.95)† 
p-value for difference across age categories 0.52 0.85
 
Ever use of prescription migraine medications  
       No 127 (9) 67 (6)  0.58 (0.43-0.79)† 53 (7)  0.65 (0.46-0.93)† 
       Yes 144 (10) 92 (8)  0.73 (0.56-0.97)† 55 (8)  0.69 (0.49-0.97)† 
p-value for difference across medication categories 0.25 0.98
* Odds ratios adjusted for age and reference year.  
† p<0.05. 
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Table 3. Relationship between a history of migraine and risks of invasive ductal and invasive lobular breast carcinomas by joint estrogen 
receptor/progesterone receptor status 
 
  Ductal carcinoma 
 Controls 
(n=1,474) 
ER+/PR+ 
(n=855) 
ER+/PR- 
(n=133) 
ER-/PR- 
(n=147) 
 No (%) No (%) OR* (95% CI) No (%) OR* (95% CI) No (%) OR* (95% CI) 
Never diagnosed with migraine 1202 (82) 739 (87) 1.00 (ref) 120 (90) 1.00 (ref) 121 (82) 1.00 (ref) 
 
Ever diagnosed with migraine 272 (19) 114 (13) 0.65 (0.51-0.83)† 13 (10) 0.49 (0.27-0.88)† 26 (18) 0.87 (0.56-1.36) 
 
Age at migraine diagnosis, years       
   <20 73 (5) 26 (3) 0.56 (0.35-0.88)† 2 (2) 0.28 (0.07-1.16) 3 (2.0) 0.37 (0.11-1.19) 
   20-39 110 (8) 57 (7) 0.82 (0.59-1.15) 6 (5) 0.56 (0.24-1.30) 15 (10) 1.24 (0.70-2.21) 
   ≥40 89 (6) 31 (4) 0.53 (0.35-0.81)† 5 (4) 0.57 (0.23-1.44) 8 (5) 0.82 (0.39-1.74) 
p-value for difference across age categories 0.80 0.43 0.37 
 
Ever use of prescription migraine medications      
   No 127 (9) 47 (6) 0.56 (0.39-0.79)† 6 (5) 0.48 (0.21-1.11) 11 (8) 0.79 (0.41-1.51) 
   Yes 144 (10) 65 (8) 0.72 (0.53-0.98)† 6 (5) 0.43 (0.19-1.00)† 15 (10) 0.95 (0.54-1.67) 
p-value for difference across medication categories 0.27 0.85 0.66 
 
  Lobular carcinoma  
 Controls 
(n=1,474) 
ER+/PR+ 
(n=560) 
ER+/PR- 
(n=110) 
 
 No (%) No (%) OR* (95% CI) No (%) OR* (95% CI)  
Never diagnosed with migraine 1202 (82) 481 (86) 1.00 (ref) 92 (84) 1.00 (ref)  
  
Ever diagnosed with migraine 272 (19) 78 (14) 0.63 (0.47-0.85)† 18 (16) 0.80 (0.47-1.36)  
  
Age at migraine diagnosis, years      
   <20 73 (5) 19 (4) 0.59 (0.34-1.03) 3 (3) 0.50 (0.15-1.65)  
   20-39 110 (8) 34 (7) 0.73 (0.47-1.13) 6 (6) 0.70 (0.30-1.66)  
   ≥40 89 (6) 23 (5) 0.50 (0.30-0.82)† 9 (8) 1.10 (0.53-2.29)  
p-value for difference across age categories 0.60 0.20  
  
Ever use of prescription migraine medications     
   No 127 (5) 35 (6) 0.57 (0.38-0.86)† 10 (9) 0.91 (0.46-1.81)  
   Yes 144 (10) 42 (8) 0.68 (0.46-1.00) 8 (7) 0.70 (0.33-1.49)  
p-value for difference across medication categories 0.53 0.60  
* Odds ratios adjusted for age and reference year. 
† p<0.05 
 
